Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

  1. Grande, E.
  2. Arranz, J.Á.
  3. De Santis, M.
  4. Bamias, A.
  5. Kikuchi, E.
  6. del Muro, X.G.
  7. Park, S.H.
  8. De Giorgi, U.
  9. Alekseev, B.
  10. Mencinger, M.
  11. Izumi, K.
  12. Schutz, F.A.
  13. Puente, J.
  14. Li, J.-R.
  15. O'Donnell, P.H.
  16. Kalebasty, A.R.
  17. Ye, D.
  18. Mariathasan, S.
  19. Bene-Tchaleu, F.
  20. Bernhard, S.
  21. Lee, C.
  22. Davis, I.D.
  23. Galsky, M.D.
Aldizkaria:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Argitalpen urtea: 2024

Alea: 25

Zenbakia: 1

Orrialdeak: 29-45

Mota: Artikulua

DOI: 10.1016/S1470-2045(23)00540-5 GOOGLE SCHOLAR

Garapen Iraunkorreko Helburuak